(Z)-N-(4-fluorophenyl)-3-[3-(trifluoromethyl)phenyl]prop-2-enamide

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (Z)-N-(4-fluorophenyl)-3-[3-(trifluoromethyl)phenyl]prop-2-enamide
• 化学式: C₁₆H₁₁F₄NO
• 分子量: 309.26
• InChiKey: UTZMZDANOHXJIL-WTKPLQERSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• NEW METHOD FOR IDENTIFYING COMPOUNDS USEFUL FOR TREATING AND/OR PREVENTING DISEASES ASSOCIATED WITH BONE LOSS
  申请人：Centre National de la Recherche Scientifique (CNRS)

  公开号：EP2331967B1

  公开（公告）日：2015-11-04
• Compounds for treating and/or preventing diseases associated with bone loss
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE -CNRS-

  公开号：EP2716285B1

  公开（公告）日：2016-04-27
• METHOD FOR IDENTIFYING COMPOUNDS USEFUL FOR TREATING AND/OR PREVENTING DISEASE-ASSOCIATED BONE LOSS
  申请人：Blangy Anne

  公开号：US20110212974A1

  公开（公告）日：2011-09-01

  The present invention concerns a method for identifying a compound which inhibits the activation of RAC GTPase by DOCK5 protein comprising the steps of (i) coexpressing the DOCK5 and the RAC proteins in a cell, wherein said DOCK5 protein induces the conversion of inactive RAC, which inactive RAC is bound to GDP, to active RAC, which active RAC is bound to GTP, (ii) contacting or not said cell with said compound, (iii) determining the conversion of inactive RAC to active RAC in the presence or absence of said compound, and (iv) selecting the compound inhibiting the conversion of inactive RAC to active RAC. Said compound is useful for treating disease-associated bone loss.
• US9091678B2
  申请人：——

  公开号：US9091678B2

  公开（公告）日：2015-07-28
• [EN] NEW METHOD FOR IDENTIFYING COMPOUNDS USEFUL FOR TREATING AND/OR PREVENTING DISEASE-ASSOCIATED BONE LOSS<br/>[FR] NOUVEAU PROCÉDÉ POUR IDENTIFIER DES COMPOSÉS UTILISÉS DANS LE TRAITEMENT ET/OU LA PRÉVENTION DE MALADIES ASSOCIÉES À LA PERTE OSSEUSE
  申请人：CENTRE NAT RECH SCIENT

  公开号：WO2010020647A2

  公开（公告）日：2010-02-25

  The present invention concerns a method for identifying a compound which inhibits the activation of RAC GTPase by DOCK5 protein comprising the steps of (i) coexpressing the DOCK5 and the RAC proteins in a cell, wherein said D0CK5 protein induces the conversion of inactive RAC, which inactive RAC is bound to GDP, to active RAC, which active RAC is bound to GTP, (ii) contacting or not said cell with said compound, (iii) determining the conversion of inactive RAC to active RAC in the presence or absence of said compound, and (iv) selecting the compound inhibiting the conversion of inactive RAC to active RAC. Said compound is useful for treating disease-associated bone loss.